Drug combination for muscle-invasive bladder cancer with bladder preservation
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—an antibody-drug conjugate (a targeted therapy that delivers cancer-killing medicine directly to cells) and an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo works better than the standard chemoradiotherapy for bladder cancer when you keep your bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have muscle-invasive bladder cancer (stage T2 to T4a, N0-N1) that has not spread to distant organs.
- Either you are not a candidate for bladder removal surgery, or you have chosen to keep your bladder and will receive chemotherapy plus radiation.
- You are in generally good health, able to do light activities (ECOG score 0–2).
- You have not had pelvic radiation or systemic cancer treatment for this disease before.
- You do not have severe dry eyes, corneal disease, or other eye conditions that might interfere with treatment.
- You do not have active inflammatory bowel disease or a history of lung issues like pneumonitis or interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) to see if it can help people with muscle-invasive bladder cancer avoid bladder removal surgery. The goal is to preserve the bladder while still treating the cancer effectively.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.